Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Olaparib Shows Promise in Breast Cancer Clinical Study

By BiotechDaily International staff writers
Posted on 21 Jul 2010
The chemotherapeutic agent olaparib has given promising results against advanced breast cancer in a group of women with BRCA1 (breast cancer 1, early onset) or BRCA2 (breast cancer 2, early onset) mutations in a phase two clinical trial conducted at 16 centers in Australia, Europe, and the U.S.

Olaparib is an inhibitor of the enzyme Poly ADP ribose polymerase (PARP). Patients with BRCA1/2 mutations may be genetically predisposed to develop some forms of cancer, and are often resistant to other forms of cancer treatment. Yet, this may also burden their cancers with a unique vulnerability, as these cancer cells have increased reliance on PARP to repair their DNA and enable them to continue dividing. This means that drugs that selectively inhibit PARP may be of significant benefit in patients whose cancers are susceptible to this treatment.

In the current study, a group of 54 women 18 years old or older with confirmed BRCA1 or BRCA2 mutations and recurrent, advanced breast cancer were placed into one of two test cohorts. The first cohort was treated with 400 mg oral olaparib twice daily and the second group of 27 patients received 100 mg oral olaparib twice daily.

Results published in the July 6, 2010, online edition of the journal the Lancet revealed that the higher dose appeared to have more activity against the disease, with one patient (4%) having a complete resolution of her tumor and ten (37%) showing substantial tumor shrinkage. Another 12 (44%) women had stable disease or some tumor shrinkage, but not enough to be considered a partial response by standard criteria. In the low dose group, six (22%) patients showed substantial shrinkage and 12 (44%) had some tumor shrinkage or stable disease.

Adverse side effects in the cohort given 400 mg twice daily were fatigue, nausea, vomiting, and anemia. The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea and fatigue.

"This is the first time that we have been able to take the genetic reason a person has developed cancer and make it a target,” said contributing author Dr. Susan M. Domchek, associate professor of medicine at the University of Pennsylvania School of Medicine (Philadelphia, USA). "Most of the time we look at what is going on in the tumor itself and then figure out how to target it. But in this situation, the women all had an inherited mutation in either the BRCA1 or BRCA2 gene and we could exploit that weakness in the tumor. It is a strategy that may cause fewer side effects for patients.”

"If you put too much stress on the cancer cell, it cannot take it, and it falls apart,” said Dr. Domchek. "These drugs may be very potent in tumor cells and much less toxic in normal cells. That is important from the perspective of cancer treatment. This is a different way of looking at cancer therapeutics. In oncology, this is really one of the first times that we have seen drugs being developed on the basis of inherited susceptibility – and that may open up a whole new avenue of drug development.”

Related Links:

University of Pennsylvania School of Medicine





SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.